Solventum (SOLV)
Health Care · Diversified Healthcare Products and Services · NYSE
A diversified healthcare technology and medical products provider focused on improving patient outcomes through specialized clinical tools and healthcare software solutions.
What Solventum does
Solventum is a healthcare company that provides a portfolio of medical products, software, and services. Its operations are organized into segments focusing on medical supplies, surgical tools, and healthcare information systems, including software and rentals for clinical and administrative workflows.
Themes: healthcare IT / software, medical devices, clinical workflow automation, healthcare analytics
Fundamentals
- Price$89.57 as of 2026-08-21 close
- Market cap$15.2B as of 2026-08-21
- 1-year return+24.4% 2025-08-21 close $72.00 → 2026-08-21 close $89.57
- P/E10.26 as of 2026-08-24
- Net margin+17.3% as of 2026-08-24
- Gross margin+54.8% as of 2026-08-24
- ROE+29.0% as of 2026-08-24
- Debt / equity1.10 as of 2026-08-24
- Revenue growth (YoY)-0.9% as of 2026-08-24
- Revenue CAGR (3y)+0.8% SEC XBRL
- Beta0.45 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How SOLV compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
SOLV is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
46.5 #1020 of 1,704 scored · #176 of 240 in Health Care
Trend 70th: it is trading 10.6% above its 50-day average, the short-term trend line; volume and participation 56th: it gapped 3.2% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is catalysts 46th: open-market insider buys in 90 days 0, the analyst consensus rating is unchanged since the prior reading. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Solventum looks technically
Solventum (SOLV) is trading 17.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 34 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range. It is trading at or near its all-time high.
Trend
8
| Distance from the 200-day | it is trading 17.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +17.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $80.98 | $80.98 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $76.34 | $76.34 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 81.22. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 34 trading days ago — a "golden cross", a bullish long-term signal | 34 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 21.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30) | 63.8 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($81.22 to $90.00) — its "stochastic" reading is 95 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 95.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $90.00 | $90.00 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.5% |
| Above the 52-week low | it is 43.0% above its 52-week low (its lowest price of the past year) | +43.0% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.5% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $90.00 (set on 2026-08-06) | $90.00 |
| Given back of the 52-week move | over the past year its closes ranged ($62.76 to $89.57), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $72.14 to $73.00. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is trading at or near its all-time high | -0.5% |
| Nearest price level | it is trading 1.3% above a support level at $88.42 — a price it turned at twice since 2025-12-02, most recently on 2026-07-29. Since 2024-08-21 it has 12 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.3% |
| All-time low | its lowest closing price on record is $47.16 (set on 2024-07-16) | $47.16 |
| Above the all-time low | it is 89.9% above its all-time low | +89.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 75% of it) | 25th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.64 between its high and its low — about 3.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.64 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $81.83 and $90.85 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $81.83 – $86.34 – $90.85 |
| Typical daily range (% of price) | its price moves about 3.0% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.0% |
| Stretch from the 200-day average | it is trading 5.0 daily ranges above its 200-day average price (17.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.79× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.8% since the prior reading | +0.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Open gap | it gapped 3.2% above the previous close 18 sessions ago and has not traded back through the level it left behind at 80.47 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.2% |
| Gap filled | a 2.4% gap up opened on 2026-08-06 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 4 sessions in a row, a +3.17% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 4 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 11.6 percentage points (the stock gained 14.0% while the market gained 2.3%) | +11.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 13.6 percentage points (the stock gained 16.7% while the market gained 3.1%) | +13.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 11.7 percentage points (the stock gained 22.8% while the market gained 11.1%) | +11.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 3.9 percentage points (the stock gained 24.4% while the market gained 20.5%) | +3.9% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 15% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.1% of the share price. | +14.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 19% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $75.55 — a volume-weighted average of daily closes over 156 sessions, not a true tick-by-tick VWAP. | +18.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $86.18 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +3.9% |
Price levels it has turned at before
SOLV last closed at $89.57 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $88.42 | Support | 1.3% below the last close | turned there twice · 2025-12-02 to 2026-07-29 |
| $86.14 | Support | 3.8% below the last close | turned there twice · 2025-02-26 to 2026-01-09 |
| $83.38 | Support | 6.9% below the last close | turned there twice · 2026-06-05 to 2026-07-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $81.22.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $94.45 and $102.63 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $81.22.
This reading has stood for 6 trading days, since 2026-08-14.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · Near the all-time high · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · all time high
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.20 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$93.92 range $70.00 – $113.00; median $95.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SOLV
- Consensus EPS estimate$1.35 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on complex global supply chains and manufacturing processes.","Significant exposure to regulatory changes and healthcare reimbursement policies.","Integration and operational risks associated with its separation from 3M."]
What changed in the latest 10-Q
AI-assisted comparison of SOLV's 10-Q filed 2026-05-05 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- New section in Overview describing tariff developments: Supreme Court IEEPA decision on February 20, 2026, Court of International Trade ruling on March 4, 2026, and potential refund processes
- Statement that Company has not recorded any potential benefit from tariff refund as of March 31, 2026
- Reference to Executive Order under Section 122 authority for new tariffs
- Statement that U.S. Administration has signaled further tariffs will be released in 2026
- Clarification in divestiture description: Transaction Agreement changed to 'Amended and Restated Transaction Agreement' with specific exclusion language
- Explicit reference to 'reportable business segments' in Operating Segments section (filed 2026-05-05)
- Removed:
- Section titled 'Transition to Standalone Company' discussing allocations, carve-out methodologies, and Spin-Off dates (present in filed 2025-11-06)
- Detailed explanations of 'Other' category acquisitions including non-health care related supply agreements from 3M at Spin-Off and dental anesthetics business sold in August 2023 (present in filed 2025-11-06)
- Reference to health care businesses retained by 3M India in connection with Spin-Off (present in filed 2025-11-06)
- Nine months ended September 30 sales and operating income tables (present in filed 2025-11-06)
- Reference to 2024 Annual Report on Form 10-K (changed to 2025 in filed 2026-05-05)
- Reworded:
- Period being reported changed from 'nine months ended September 30, 2025 and 2024' to 'three months ended March 31, 2026 and 2025'
- Reference to '2024 Annual Report on Form 10-K' changed to '2025 Annual Report on Form 10-K' (filed 2026-05-05)
- Description of Agreement changed from 'additional Agreement' to 'Amended and Restated Transaction Agreement'
- Divestiture impacts definition simplified from listing multiple business divestitures to stating 'lost sales from the Company's Purification and Filtration business that was sold in September 2025'
- Segment description changed from 'three business segments' to 'three reportable business segments' (filed 2026-05-05)
- Notes:
- The two filings cover different reporting periods (Q3 2025 nine months vs Q1 2026 three months), making direct comparison of financial tables not directly comparable
- Tariff section is substantively new content reflecting developments between November 2025 and May 2026 filing dates
- MD&A structure and content differ due to different reporting periods and company maturity stages (post-Spin-Off transition period vs established operations)
Risk Factors
- Added:
- Finance leases of $207 million appeared in newer filing's balance sheet (March 31, 2026) with corresponding 'Right-of-use assets obtained in exchange for finance lease liability' of $207 million in cash flow statement supplemental information
- Treasury stock line item added to newer filing showing 922,636 shares at cost of $67 million as of March 31, 2026
- Purchase of treasury stock of $67 million appears in newer filing's financing activities and statement of changes in equity
- Removed:
- Nine-month comparative financial data present in older filing (September 30, 2025) is absent from newer filing which only shows three-month periods
- Gain on sale of business of $1,518 million (three months and nine months ended September 30, 2025) is not present in newer filing
- Loss on debt extinguishment, net of $82 million (three months ended September 30, 2025) is not present in newer filing
- 'Net Parent Investment' column that appeared in older filing's statements of changes in equity is completely removed from newer filing
- Short-term borrowings and current portion of long-term debt of $200 million as of December 31, 2024 is replaced with $505 million as of March 31, 2026, representing a significant increase rather than the zero amount shown as of September 30, 2025
- Reworded:
- Reporting period changed from 'Three months ended September 30' (older filing) to 'Three months ended March 31' (newer filing)
- Balance sheet comparison date changed from 'September 30, 2025 and December 31, 2024' to 'March 31, 2026 and December 31, 2025'
- Cash flows statement period changed from 'Nine months ended September 30' to 'Three months ended March 31'
- Pension and postretirement benefits line item caption changed from 'Pension and postretirement benefit expense' to 'Pension and postretirement benefits' in cash flow statement
- Notes:
- The two filings cover different fiscal periods (Q3 2025 vs Q1 2026) and different balance sheet dates, making some comparisons reflect timing differences rather than operational changes
- The older filing contained a significant one-time gain on sale of business ($1,518 million) and related transaction costs that do not appear in the newer period, affecting comparability of operating results
- Different accounting presentation of parent company equity relationships between the two filings (Net Parent Investment in older filing completely removed in newer filing)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for SOLV — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for SOLV from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding SOLV as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 19,422,144
- Reported value $1,268,266,007
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SOLV had 3,512,330 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SOLV had 2.06% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.02 days to cover at the same settlement.
- Reported short interest (shares) 3,512,330
- Short interest (% of shares outstanding) 2.06%
- Prior settlement (shares) 4,297,389
- Reported change -18.27%
- Days to cover (reported) 3.02
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- Baxter International (BAX)
- Becton, Dickinson and Company (BDX)
- Stryker (SYK)
- Nuance Communications (Microsoft) (MSFT)
- Cerner (Oracle) (ORCL)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SOLV vs…
Solventum is found in…
Frequently asked questions
What does Solventum (SOLV) do?
Solventum is a healthcare company that provides a portfolio of medical products, software, and services. Its operations are organized into segments focusing on medical supplies, surgical tools, and healthcare information systems, including software and rentals for clinical and administrative workflows.
What sector is Solventum (SOLV) in?
Solventum (SOLV) is classified in the Health Care sector. Its industry is Diversified Healthcare Products and Services. It trades on NYSE.
Who are Solventum's (SOLV) competitors?
Notable peers of Solventum (SOLV) include Medtronic, Baxter International, Becton, Dickinson and Company, Stryker and Nuance Communications (Microsoft). This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in SOLV?
Yes — we hold 2 matched STOCK Act disclosures for SOLV from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Solventum (SOLV) overbought or oversold right now?
Solventum (SOLV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 64, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SOLV come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.